An observational cohort study led by Dr. Carolyn Taylor from the University of Oxford in the U.K. showed that mortality rates for women diagnosed with early breast cancer in England decreased from a 5-year mortality risk of 14% in the 1990s to 5% in 2010-2015.

The researchers analyzed data from 512,447 women. The study included data from the England National Cancer Registration and Analysis Service between January 1993 and December 2015, with a follow-up until December 2020.

The study’s results might also help providers identify prognostic risk factors for women diagnosed with early breast cancer.
The study was published in BMJ.

• MIT scientists developed a novel method to introduce certain cancer-related mutations into mouse models. CRISPR genome-editing technology has been used to “design models of multiple mutations of the cancer-causing gene, Kras, in various organs.” The novel method is quite revolutionary, and much more efficient than the traditional labor- and time-consuming approach. The study was published in Nature Biotechnology.
• Researchers from German Cancer Research Center and other institutions worldwide conducted a systematic review and meta-analysis on vitamin D3 supplementation impact on mortality and prognosis in cancer, which showed that taking vitamin D daily could help in reducing cancer death risk by 12%. The same review demonstrated that older people benefit more from taking the vitamin than younger people and that it works best when taken preventatively. The systematic review was published in Ageing Research Reviews.
• While breast density was long linked to breast cancer risk, the new study demonstrated that the slower pace of changes in breast density in one breast compared to the other breast in the same patient over time also seems to be linked to cancer risk. The study was published in JAMA Oncology.
• A new study demonstrated that interrupting a standard hormone therapy, given to prevent breast cancer recurrence, for conceiving a child “appears safe in the short term.” The study was published in the New England Journal of Medicine
  

In the ‘Oncology On-The-Go’ Podcast posted on April 24th, 2023, Dr. Ritu Salani and Dr. Dana Chase discussed results presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting with CancerNetwork®.

Dr. Salani and Dr. Chase are providers at the University of California Los Angeles (UCLA). They spoke about key findings and possibilities for improving patients’ quality of life. They reviewed the results from those three trials:

• Trial NCT03914612
  The results are published in The New England Journal of Medicine: Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
• Trial NCT03981796
  The results are published in The New England Journal of Medicine: Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
• Trial NCT01847274
  The results are published in the Journal of clinical oncology: Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial